

# EUPATI 2018 Evaluation Report



The following report summarises in an easy to read format the activities of the EUPATI Programme to since the 2017 Mid-Year Report. The measures evaluated are based on the objectives and miles stones defined under IMI-EUPATI and in the subsequent Steering Group discussions and described in the EUPATI Programme Work Plan 2018. Further details are provided in the appendicies distributed with this document and stored in the Evaluation 2018 Folder stored on Box.com. 2018 marked the second of the three year bridging phase of the EUPATI programme, with the aim to focus on sustainability models to secure EUPATI's mid-, and long-term future, whilst continuing the delivery of three key pillars that make EUPATI a successful programme: the Patient Expert Training Course, the Toolbox, and the EUPATI National Platforms network. The visual traffic light system used in this report provides an indication of completion of an objective or milestone, or the need for continued work. Details are provided next to each line item in the table.

## Highlights

<p>More than <b>1 million</b> Toolbox users since launch (users <b>grown 115% in 2018 vs 2017</b>)</p>	<p><b>48</b> representatives from <b>20 Countries</b> attended the ENP AGM which represents a <b>23% increase</b> in attendance from 2017</p>	<p><b>New ENP Event</b> ENP Capacity Building event hosted in May 2018</p>	<p><b>EUPATI Guidances published as peer-reviewed</b> articles in <b>Frontiers</b></p>	<p><b>Editorial Board</b> reviewed material for <b>F2F events</b> and <b>3 Editorial Board Meetings</b></p>	<p>Launch of <b>Danish Toolbox</b> Sweden, Portugal and Romania also coming soon</p>	<p><b>79 participants</b> attended an <b>ENP specific webinar</b> focusing on the 4 main challenges facing ENPs</p>	<p>Launch of <b>EFOEUPATI - Ensuring the Future of EUPATI</b></p>
<p><b>New EUPATI National Platform Executive Committee</b> elected for <b>2018</b> 4 members remained for 2nd term <b>2</b> retired <b>2</b> new members joined</p>	<p><b>95% of trainees</b> felt that the training experience will be useful in their advocacy work* <i>*based on evaluation survey results taken by 51 trainees</i></p>	<p><b>Currently 54 trainees</b> on the course</p>	<p><b>16 Countries</b> provided their views in the ENP survey on potential future business models for EUPATI</p>	<p><b>7 out of 10 models</b> from 2017 were evaluated  2 models to be developed: <b>Copayment</b> and <b>Payback</b></p>	<p><b>New ENP Finland</b> established</p>	<p>ENP Network coordination boosted via <b>EFO EUPATI</b> <b>3 ENP Regional Groups</b> established Regional Officer hired</p>	<p><b>14 Additional Hands on Sessions</b> for Events 1 &amp; 2</p>

## Sustaining Partners in 2018



The European Patients' Academy on Therapeutic Innovation received the support from pharmaceutical companies and public organisations (patient organisations, not-for-profit organisations, academic institutions) in 2018. Without your financial or in-kind contribution, EUPATI would have not been able to deliver all of the milestones you can find in the present document.

EUPATI would like to thank each and every partner for contributing to our Programme and to ensuring that patients and patient representatives receive the best education and training on medicines research and development.

Thank you!

abbvie

AMGEN

AstraZeneca



UNIVERSITY OF COPENHAGEN

BIO PEOPLE

Bristol-Myers Squibb

Boehringer Ingelheim

DIA DEVELOP INNOVATE ADVANCE

EA TG European AIDS Treatment Group

EF GCP

EPF European Patients Forum

EURORDIS RARE DISEASES EUROPE

gsk

IPPOSI

ISPOR Improving healthcare decisions

Janssen

MERCK

MSD

NOVARTIS

novo nordisk

Pfizer

Roche

Takeda

ucb